Contents
Voltron Therapeutics, Inc. aims to improve cell mediated responses to combat infectious diseases, such as COVID-19 and specific forms of cancers, using the advanced and proprietary VaxCelerate Self-Assembling Vaccine Design developed by specialists at the Massachusetts General Hospital (MGH) and the Vaccine & Immunotherapy Center. Voltron has an exclusive license to this technology from MGH.
Timeline
No Timeline data yet.
Further Resources
Title
Author
Link
Type
Date
Dr. Poznansky on what it takes to develop a vaccine during the coronavirus pandemic
Web
References
Company attributes
Location
B2X
CEO
Pitchbook URL
Legal Name
Voltron Therapeutics, Inc.
Subsidiary
Spun Out From
Founded Date
2017
Email Address
info@luciuspartners.com-1
Phone Number
+16463355923
Total Funding Amount (USD)
12,000,000
Latest Funding Round Date
August 2021
Business Model
Licensing
Country
Other attributes
Company Operating Status
Active
